Replication and virus-induced transcriptome of HADV-5 in normal host cells versus cancer cells - differences of relevance for adenoviral oncolysis

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Dorer, Dominik E ^a   Holtrup, Frank ^a   Fellenberg, Kurt ^a,b   Kaufmann, Johanna K ^a   Engelhardt, Sarah ^a   Hoheisel, Jörg D ^a   Nettelbeck, Dirk M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; ONCOLYTIC ADENOVIRUS; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTOME;

ADENOVIRUS 5; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL CYCLE S PHASE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; PROTEIN EXPRESSION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; BRONCHI; CELL LINE, TUMOR; CLUSTER ANALYSIS; CYTOPATHOGENIC EFFECT, VIRAL; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; GENOME, VIRAL; HUMANS; MOLECULAR SEQUENCE ANNOTATION; NEOPLASMS; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; S PHASE; TRANSCRIPTOME; UP-REGULATION; VIRUS REPLICATION;

EID: 82355182018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027934     Document Type: Article

References (51)

1. Alemany R, Balague C, Curiel DT, (2000) Replicative adenoviruses for cancer therapy. Nat Biotechnol 18: 723-727.
2. Yamamoto M, Curiel DT, (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther 18: 243-250.
3. McConnell MJ, Imperiale MJ, (2004) Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15: 1022-1033.
4. Dorer DE, Nettelbeck DM, (2009) Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61: 554-571.
5. Reid T, Warren R, Kirn D, (2002) Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9: 979-986.
6. Liu TC, Galanis E, Kirn D, (2007) Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117.
7. Glasgow JN, Everts M, Curiel DT, (2006) Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 13: 830-844.
8. Cody JJ, Douglas JT, (2009) Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 16: 473-488.
9. Wold WS, Horwitz MS, (2006) Adenoviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, editors. Fields Virology. 5th ed Philadelphia Lippincott Williams & Wilkins pp. 2395-2436.
10. Yan W, Kitzes G, Dormishian F, Hawkins L, Sampson-Johannes A, et al. (2003) Developing novel oncolytic adenoviruses through bioselection. J Virol 77: 2640-2650.
11. Subramanian T, Vijayalingam S, Chinnadurai G, (2006) Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 80: 2000-2012.
12. Gros A, Martinez-Quintanilla J, Puig C, Guedan S, Mollevi DG, et al. (2008) Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res 68: 8928-8937.
13. Sauthoff H, Heitner S, Rom WN, Hay JG, (2000) Deletion of the adenoviral E1b-19 kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 11: 379-388.
14. Schmitz M, Graf C, Gut T, Sirena D, Peter I, et al. (2006) Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses. Gene Ther 13: 893-905.
15. Rohmer S, Quirin C, Hesse A, Sandmann S, Bayer W, et al. (2009) Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner. Virology 395: 243-254.
16. Weitzman MD, Ornelles DA, (2005) Inactivating intracellular antiviral responses during adenovirus infection. Oncogene 24: 7686-7696.
17. Berk AJ, (2006) Adenoviridae: The viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, editors. Fields Virology. 5th ed Philadelphia Lippincott Williams & Wilkins pp. 2356-2394.
18. Horwitz MS, (2004) Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med 6 (Suppl 1): S172-183.
19. Pelka P, Ablack JN, Fonseca GJ, Yousef AF, Mymryk JS, (2008) Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. J Virol 82: 7252-7263.
20. Jones N, Shenk T, (1979) An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc Natl Acad Sci U S A 76: 3665-3669.
21. Berk AJ, (2005) Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24: 7673-7685.
22. Ikeda MA, Nevins JR, (1993) Identification of distinct roles for separate E1A domains in disruption of E2F complexes. Mol Cell Biol 13: 7029-7035.
23. Felsani A, Mileo AM, Paggi MG, (2006) Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25: 5277-5285.
24. Martin ME, Berk AJ, (1998) Adenovirus E1B 55K represses p53 activation in vitro. J Virol 72: 3146-3154.
25. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL, (1998) The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16: 349-357.
26. Zhao H, Granberg F, Elfineh L, Pettersson U, Svensson C, (2003) Strategic attack on host cell gene expression during adenovirus infection. J Virol 77: 11006-11015.
27. Zhao H, Granberg F, Pettersson U, (2007) How adenovirus strives to control cellular gene expression. Virology 363: 357-375.
28. Granberg F, Svensson C, Pettersson U, Zhao H, (2005) Modulation of host cell gene expression during onset of the late phase of an adenovirus infection is focused on growth inhibition and cell architecture. Virology 343: 236-245.
29. Granberg F, Svensson C, Pettersson U, Zhao H, (2006) Adenovirus-induced alterations in host cell gene expression prior to the onset of viral gene expression. Virology 353: 1-5.
30. Miller DL, Myers CL, Rickards B, Coller HA, Flint SJ, (2007) Adenovirus type 5 exerts genome-wide control over cellular programs governing proliferation, quiescence, and survival. Genome Biol 8: R58.
31. Monfared P, Winkeler A, Klein M, Li H, Klose A, et al. (2008) Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo. Cancer Res 68: 5932-5940.
32. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, et al. (2000) Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 74: 6147-6155.
33. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM, (2002) An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 62: 3438-3447.
34. Sauthoff H, Pipiya T, Heitner S, Chen S, Bleck B, et al. (2004) Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Mol Ther 10: 749-757.
35. Toth K, Djeha H, Ying B, Tollefson AE, Kuppuswamy M, et al. (2004) An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling. Cancer Res 64: 3638-3644.
36. Wang Y, Xue SA, Hallden G, Francis J, Yuan M, et al. (2005) Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res 65: 1523-1531.
37. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, et al. (2009) Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res 15: 1730-1740.
38. Oberg D, Yanover E, Adam V, Sweeney K, Costas C, et al. (2010) Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res 16: 541-553.
39. Liu TC, Wang Y, Hallden G, Brooks G, Francis J, et al. (2005) Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther 12: 1333-1346.
40. Lohr K, Hartmann O, Schafer H, Dobbelstein M, (2003) Mutual interference of adenovirus infection and myc expression. J Virol 77: 7936-7944.
41. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT, (2002) Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 62: 4663-4670.
42. Simon P, (2003) Q-Gene: processing quantitative real-time RT-PCR data. Bioinformatics 19: 1439-1440.
43. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, et al. (1992) Analysis of gene expression in single live neurons. Proc Natl Acad Sci U S A 89: 3010-3014.
44. Fellenberg K, Hauser NC, Brors B, Hoheisel JD, Vingron M, (2002) Microarray data warehouse allowing for inclusion of experiment annotations in statistical analysis. Bioinformatics 18: 423-433.
45. Cleveland WS, (1981) LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression. The American Statistician 35: 54.
46. Beissbarth T, Fellenberg K, Brors B, Arribas-Prat R, Boer J, et al. (2000) Processing and quality control of DNA array hybridization data. Bioinformatics 16: 1014-1022.
47. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
48. Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, et al. (2001) Correspondence analysis applied to microarray data. Proc Natl Acad Sci U S A 98: 10781-10786.
49. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
50. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
51. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.